BIOSPECIMEN COLLECTION STUDY

TScan Therapeutics  200-05

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients with Autoimmune Disease.

EXOCRINE PANCREATIC INSUFFICIENCY

Abbvie M21-432

Phase 4 study to assess symptoms in subjects with Cystic Fibrosis or Chronic Pancreatitis treated with Creon with an alternate source of active pharmaceutical ingredient.

NONALCOHOLIC STEATOHEPATITIS (NASH)

Gilead Sciences, Inc. GS-US-454-6075

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

PRIMARY BILIARY CHOLANGITIS

Cour CNP-104-5.001

A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18 – 75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA.

CROHN’S DISEASE

Abbvie M20-371

A Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-154 in subjects with moderately to severely active Crohn’s disease

Arena Cultivate APD334-202

A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease. *

AstraZeneca D5271C000001

A 52-week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease (INTREPID Lead-In).

Janssen Duet UC 78934804UCO2001

A Phase 2b Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis.

Janssen Progress CD CNTO1959CRD3007

A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection.

LEFT SIDED ULCERATIVE COLITIS

Index CS UC 01-21

A Phase 3 study to evaluate the efficacy and safety of  Cobitolimod (PR) as an induction and maintenance therapy in participants with moderate to severe Left sided UC.

ULCERATIVE COLITIS

Arena  Gladiator APD334-210

A Randomized, Double-Blind, Placebo-Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis. *  

AstraZeneca Expedition D5272C00001

A 54-week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (Expedition Lead-In).

BMS IM047029

A Phase 4, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice.

Janssen DUET UC 78934804UCO2001

A Phase 2b Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis.

Seres Therapeutics

UC Microbiome Prospective Stool Collection Study: A prospective stool collection from patients with active Ulcerative Colitis.

IgG4-RELATED DISEASE

Zenas BioPharma ZB012-03-001

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with IgG4-Related Disease (INDIGO).

Study medications, labs and other procedures are provided free of charge to patients and travel will be compensated.

Contact the research office at 239-649-1336 with any questions.